Within the framework of the conference, “Biomarkers as a tool to detect cervical cancer”, health specialists agreed that the Preventix test is a viable alternative for the timely detection of cervical cancer.
During the conference, the medical director of MAC CDMX hospitals, Marco Toledo, and the general director of MAC CDMX Hospitals, Gabriel Ayerdi, announced that they will be the first to have and implement the Preventix test in their hospitals.
At the event, doctors specialized in the subject explained that this disease affects hundreds of thousands of women in Mexico every year, so it is essential to deal with it in the most effective way possible and highlighted the contribution that Timser has made to detect this type of cancer.
In turn, Denisse Acuña González, an obstetrician-gynecologist, explained that cervical cancer cannot be detected in time and, to a large extent, this is due to a great lack of information and education.
“Education in the population is a priority set that we must all do, especially those populations that are developing or in indigenous communities where a sexual life begins from a very early age,” he said.
For his part, Dr. David Cantú, Director of Research at the National Cancer Institute, stressed that this disease is not generated overnight, but rather takes a long time to develop, approximately 10 to 20 years, so it is possible prevent it one hundred percent.
To achieve this, Dr. Ruth Esparza mentioned the importance of biomarkers as an early detection method for cervical cancer.
“A biomarker is a biomolecule. What it does is detect what is happening in a process, whether in a pathology such as cancer or diabetes, and know that we can find it in time,” he explained.
In turn, Eduardo Cervera Cevallos, director of teaching at the National Cancer Institute, established that with Preventix it is possible to detect precancerous lesions and cancer itself, with just a drop of blood.
Approximately 70 percent of cases are invisible, so the disease is not detected until it is already advanced.
“The treatment of a woman in stage zero is very low cost. However, in phase three, the treatment costs between two and three million pesos. This can be avoided by detecting it before or even prevent it from the beginning. […] We want to send cancer through a tube”, he concluded.
